Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614134 | 1.00 | PPM1B (0.49) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL20489196 | 1.00 | PPM1B (0.49) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL28403234 | 1.00 | PPM1B (0.49) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL34472936 | 0.92 | PPM1B (0.46) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL34468392 | 0.87 | PPM1B (0.46) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL32677632 | 0.81 | PPM1B (0.44) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL32677631 | 0.81 | PPM1B (0.44) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL15712143 | 0.80 | PPM1B (0.53) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL23780231 | 0.78 | — | — | |
| SCHEMBL5778032 | 0.78 | PPM1B (0.43) | PPM1BPTPN1PPP1CCMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-9714235-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-9714235-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-20160168129-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| US-20160168129-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| WO-2015007219-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | ABL1, MAP4K2, DMPK | PPM1B 562/4885PTPN1 742/4885PPP1CC 715/4885 |
| US-20160168129-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | ABL1, MAP4K2, DMPK | PPM1B 562/4885PTPN1 742/4885PPP1CC 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.